title: Treatment of Helicobacter pylori infection 2011.
abstract: This article reviews the literature published pertaining to Helicobacter pylori eradication over the last year. The general perception among clinicians and academics engaged in research on H. pylori has been that eradication rates for first-line therapies are falling, although some data published this year have cast doubt on this. The studies published this year have therefore focussed on developing alternative strategies for the first-line eradication of H. pylori. In this regard, clear evidence now exists that both levofloxacin and bismuth are viable options for first-line therapy. The sequential and "concomitant" regimes have also been studied in new settings and may have a role in future algorithms also. In addition, data have emerged that the probiotic Saccharomyces boulardii may be a useful adjunct to antibiotic therapy. Other studies promote individualized therapies based on host polymorphisms, age, and other such demographic factors.
authors: Department of Gastroenterology, Adelaide and Meath Hospital incorporating the National Children's Hospital/Trinity College Dublin, Dublin, Ireland. jpoconno@tcd.ie
authors: Anthony
authors: A
authors: O'Connor
authors: Javier P
authors: JP
authors: Gisbert
authors: Deirdre
authors: D
authors: McNamara
authors: Colm
authors: C
authors: O'Morain
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000235:genetics / Q000382:microbiology; D016480:Helicobacter pylori / Q000187:drug effects*; D006801:Humans; D019936:Probiotics / Q000627:therapeutic use*; D054328:Proton Pump Inhibitors / Q000627:therapeutic use*
chemical_list: D000900:Anti-Bacterial Agents; D054328:Proton Pump Inhibitors